LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome
- 149 Downloads
This study systematically assessed the weight management effects of a novel experimental DNA-customized nutraceutical, LG839 (LifeGen®, Inc., La Jolla, CA, USA).
A total of 1058 subjects who participated in the overall D.I.E.T. study were genotyped and administered an LG839 variant based on polymorphic outcomes. A subset of 27 self-identified obese subjects of Dutch descent, having the same DNA pattern of four out of the five candidate genes tested (chi-square analysis) as the entire data set, was subsequently evaluated. Simple t tests comparing a number of weight management parameters before and after 80 days of treatment with LG839 were performed.
Significant results were observed for weight loss, sugar craving reduction, appetite suppression, snack reduction, reduction of late night eating (all P<0.01), increased perception of overeating, enhanced quality of sleep, increased happiness (all P<0.05), and increased energy (P<0.001). Polymorphic correlates were obtained for a number of genes (LEP, PPAR-γ2, MTHFR, 5-HT2A, and DRD2 genes) with positive clinical parameters tested in this study. Of all the outcomes and gene polymorphisms, only the DRD2 gene polymorphism (A1 allele) had a significant Pearson correlation with days on treatment (r=0.42, P=0.045).
If these results are confirmed in additional rigorous, controlled studies, we carefully suggest that DNA-directed targeting of certain regulator genes, along with customized nutraceutical intervention, provides a unique framework and strategic modality to combat obesity.
KeywordsLG839 neurotransmitters obesity reward deficiency syndrome sugar craving behavior weight loss
Unable to display preview. Download preview PDF.
- 1.Institute of Medicine. Weighting the Options: Criteria for Evaluating Weight Management Programs. Washington DC: National Academy Press; 1995.Google Scholar
- 2.National Institutes of Health, National Heart, Lung and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the Evidence Report. NIH Publication No. 98-4083. Bethesda, MD: NIH; 1998.Google Scholar
- 3.World Health Organization. International Classification of Diseases, Ninth Revision, Clinical Modification. Geneva: WHO; 1975. Available at: www.cdc.gov/nchs/icd9.htmRTF. Accessed July 2008.Google Scholar
- 4.US Food and Drug Administration, Department of Health and Human Services. Final Rules: Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body. Effective February 7, 2000. FDA Docket No. 98N-0044. Rockville, MD: FDA; 2000;65.Google Scholar
- 5.Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity. JAMA. 1996;276:1907–1915.Google Scholar
- 6.U.S. Census Bureau web site. Available at: www.census.gov. Accessed July 2008.Google Scholar
- 7.Stobbe M. Survey: most obese claim to eat healthy. LiveScience web site. Available at: www.livescience.com/health/060802_ap_obese_selfimage.html. August 15, 2006. Accessed July 2008.Google Scholar
- 11.Blum K, Kozlowski GP. Ethanol and neuromodulator interactions: a cascade model of reward. In: Ollat H, Parvez S, Parvez H, eds. Alcohol and Behavior. Utrecht: VSP Press; 1990:131–149.Google Scholar
- 12.Blum K, Cull JG, Braverman ER, et al. Reward deficiency syndrome. Am Sci. 1996;84:132–145.Google Scholar
- 16.Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive and compulsive behaviors. J Psychoactive Drugs. 2000;32(suppl. 1–4):1–112.Google Scholar
- 24.Blum K, Trachtenberg MC, Cook DW. Neuronutrient effects on weight loss in carbohydrate bingers: an open clinical trial. Curr Ther Res. 1990;48:217–233.Google Scholar
- 34.Thom E. Hydroxycitrate (HCA) in the treatment of obesity. Int J Obes. 1996;20:75.Google Scholar
- 39.Fisher LD, van Belle G. Biostatistics: a Methodology for the Health Sciences. New York: Wiley; 1993.Google Scholar
- 40.Food and Drug Administration Center For Drug Evaluation and Research (CDER). Joint Meeting of the Nonprescription Drugs and the Endocrinologic & Metabolic Drugs Advisory Committee. January 23, 2006. Available at: www.fda.gov/OHRMS/DOCKETS/ac/06/questions/2006-4201q1.pdf. Accessed July 2008.Google Scholar
- 51.Wainer H. The most dangerous equation. Am Sci. 2007;95:249–256.Google Scholar